MAPT and Alzheimer disease: In keeping with the recent failure of anti-Aβ-based immunotherapies to improve cognition in clinical trials[5], regulation of Aβ pathology may not be sufficient to fully account for the action of IVIg in AD, particularly in the absence of an amelioration of tau pathology and synaptic defects.